Chimerix (CMRX) Revenue & Revenue Breakdown
Chimerix Revenue Highlights
Latest Revenue (Y)
$324.00K
Latest Revenue (Q)
$129.00K
Main Segment (Y)
Contract And Grant
Chimerix Revenue by Period
Chimerix Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $324.00K | -99.04% |
2022-12-31 | $33.82M | 1609.15% |
2021-12-31 | $1.98M | -63.16% |
2020-12-31 | $5.37M | -57.09% |
2019-12-31 | $12.52M | 73.49% |
2018-12-31 | $7.22M | 60.57% |
2017-12-31 | $4.49M | -21.19% |
2016-12-31 | $5.70M | -47.02% |
2015-12-31 | $10.76M | 166.39% |
2014-12-31 | $4.04M | -7.55% |
2013-12-31 | $4.37M | -87.04% |
2012-12-31 | $33.72M | 178.65% |
2011-12-31 | $12.10M | 605.60% |
2010-12-31 | $1.72M | - |
Chimerix Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-06-30 | $129.00K | 100.00% |
2024-03-31 | - | -100.00% |
2023-12-31 | $4.00K | -63.64% |
2023-09-30 | $11.00K | -57.69% |
2023-06-30 | $26.00K | -90.81% |
2023-03-31 | $283.00K | -65.23% |
2022-12-31 | $814.00K | -97.50% |
2022-09-30 | $32.55M | 7298.86% |
2022-06-30 | $440.00K | 2833.33% |
2022-03-31 | $15.00K | -67.39% |
2021-12-31 | $46.00K | -57.01% |
2021-09-30 | $107.00K | -72.63% |
2021-06-30 | $391.00K | -72.75% |
2021-03-31 | $1.44M | 28.13% |
2020-12-31 | $1.12M | -30.39% |
2020-09-30 | $1.61M | 14.76% |
2020-06-30 | $1.40M | 12.97% |
2020-03-31 | $1.24M | -81.66% |
2019-12-31 | $6.77M | 245.61% |
2019-09-30 | $1.96M | 36.16% |
2019-06-30 | $1.44M | -38.96% |
2019-03-31 | $2.36M | -51.56% |
2018-12-31 | $4.86M | 1218.16% |
2018-09-30 | $369.00K | -69.07% |
2018-06-30 | $1.19M | 51.01% |
2018-03-31 | $790.00K | -57.16% |
2017-12-31 | $1.84M | 105.57% |
2017-09-30 | $897.00K | 32.89% |
2017-06-30 | $675.00K | -37.38% |
2017-03-31 | $1.08M | -45.56% |
2016-12-31 | $1.98M | 203.22% |
2016-09-30 | $653.00K | -64.53% |
2016-06-30 | $1.84M | 49.92% |
2016-03-31 | $1.23M | -60.51% |
2015-12-31 | $3.11M | 36.94% |
2015-09-30 | $2.27M | -45.18% |
2015-06-30 | $4.14M | 234.65% |
2015-03-31 | $1.24M | 7.09% |
2014-12-31 | $1.16M | -2.45% |
2014-09-30 | $1.19M | 28.94% |
2014-06-30 | $919.00K | 17.82% |
2014-03-31 | $780.00K | -11.26% |
2013-12-31 | $879.00K | -3.62% |
2013-09-30 | $912.00K | 12.87% |
2013-06-30 | $808.00K | -54.38% |
2013-03-31 | $1.77M | -50.54% |
2012-12-31 | $3.58M | -82.83% |
2012-09-30 | $20.86M | 236.12% |
2012-06-30 | $6.21M | 101.59% |
2012-03-31 | $3.08M | - |
Chimerix Revenue Breakdown
Chimerix Revenue Breakdown by Product
Annual Revenue by Product
Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
---|---|---|---|---|---|
Procurement | - | $31.97M | - | - | - |
Royalty | - | $375.00K | - | - | - |
Contract And Grant | $275.00K | - | - | - | - |
License | $49.00K | $536.00K | $51.00K | $98.00K | $4.92M |
Contract And Grant Revenue | - | $942.00K | $1.93M | - | - |
Contract | - | - | - | $5.27M | $7.60M |
Quarterly Revenue by Product
Product/Service | Jun 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Contract And Grant | $129.00K | $4.00K | $11.00K | $26.00K | $234.00K | $503.00K | - | - | - | - | - | - | - | - | - | - |
License | - | - | $49.00K | $81.00K | $440.00K | $15.00K | $46.00K | $2.00K | $1.00K | $2.00K | $4.00K | $18.00K | $6.00K | $70.00K | - | - |
Procurement | - | - | - | $31.97M | - | - | - | - | - | - | - | - | - | - | - | - |
Contract and Grant | - | - | - | - | - | - | - | - | $105.00K | $390.00K | $1.43M | - | - | - | - | - |
Contract | - | - | - | - | - | - | - | - | - | - | - | - | $1.12M | $1.59M | $1.40M | $1.17M |
Chimerix Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
CTMX | CytomX Therapeutics | $101.21M | $25.11M |
SPRO | Spero Therapeutics | $96.73M | $10.20M |
MREO | Mereo BioPharma Group | $10.00M | - |
ASMB | Assembly Biosciences | $7.16M | $5.79M |
CMRX | Chimerix | $324.00K | $129.00K |
XFOR | X4 Pharmaceuticals | - | $563.00K |
DAWN | Day One Biopharmaceuticals | - | $20.07M |
NXTC | NextCure | - | - |
TIL | Instil Bio | - | - |
NLTX | Neurogene | - | - |
TERN | Terns Pharmaceuticals | - | - |
ACHL | Achilles Therapeutics | - | - |
CMRX Revenue FAQ
What is Chimerix’s yearly revenue?
Chimerix's yearly revenue for 2023 was $324K, representing a decrease of -99.04% compared to 2022. The company's yearly revenue for 2022 was $33.82M, representing an increase of 1609.15% compared to 2021. CMRX's yearly revenue for 2021 was $1.98M, representing a decrease of -63.16% compared to 2020.
What is Chimerix’s quarterly revenue?
Chimerix's quarterly revenue for Q2 2024 was $129K, a 100.00% increase from the previous quarter (Q1 2024), and a 396.15% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a -100.00% decrease year-over-year (Q1 2023). CMRX's quarterly revenue for Q4 2023 was $4K, a -63.64% decrease from the previous quarter (Q3 2023), and a -99.51% decrease year-over-year (Q4 2022).
What is Chimerix’s revenue growth rate?
Chimerix's revenue growth rate for the last 3 years (2021-2023) was -83.63%, and for the last 5 years (2019-2023) was -97.41%.
What are Chimerix’s revenue streams?
Chimerix's revenue streams in c 23 are Contract And Grant, and License. Contract And Grant generated $275K in revenue, accounting 84.88% of the company's total revenue License generated $49K in revenue, accounting 15.12% of the company's total revenue, down -90.86% year-over-year.
What is Chimerix’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Chimerix was Contract And Grant. This segment made a revenue of $275K, representing 84.88% of the company's total revenue.